# GERN catalysts: GERON CORP PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gern/catalysts

> GERON CORP (GERN) has 2 upcoming catalysts. The next is the RYTELO (imetelstat) topline data readout, Jun to Sep 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | GERON CORP |
| Ticker | GERN (Nasdaq) |
| SEC CIK | 886744 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/gern |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2023 | [RYTELO (imetelstat) topline data readout](https://sec-api.dev/pdufa/imetelstat) | GERN |  | completed, positive | "Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in the U.S. for lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO's activity in other indications." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/886744/000088674426000041/gern-20260930.htm)) |
| March 14, 2024 | [RYTELO (imetelstat) FDA advisory committee meeting](https://sec-api.dev/pdufa/imetelstat) | GERN |  | completed, positive | "The Committee will discuss new drug application (NDA) 217779 for imetelstat for injection, submitted by Geron Corporation. The proposed indication for this product is for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/march-14-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-03142024)) |
| June 6, 2024 | [RYTELO (imetelstat) FDA approval](https://sec-api.dev/pdufa/imetelstat) | GERN | To treat low- to intermediate-1 risk myelodysplastic syndromes | completed, approved | "Rytelo \| imetelstat \| 6/6/2024 \| To treat low- to intermediate-1 risk myelodysplastic syndromesDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| February 26, 2025 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000095017025027331/gern-ex99_1.htm)) |
| March 31, 2025 | [RYTELO (imetelstat) FDA approval](https://sec-api.dev/pdufa/imetelstat) | GERN |  | completed, approved | "The decrease in research and development expenses for the three months ended March 31, 2025, compared to the same period in 2024, was primarily due to decreased clinical trial costs associated with a decrease of activity in our IMerge MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, versus being expensed in the prior period." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/886744/000088674425000010/gern-20250331.htm)) |
| May 7, 2025 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/gern-20250331xexx991.htm)) |
| June 30, 2025 | [RYTELO (imetelstat) FDA approval](https://sec-api.dev/pdufa/imetelstat) | GERN |  | completed, approved | "Total product revenue, net for the three and six months ended June 30, 2025, was $49.0 million and $88.4 million, compared to $780,000 for the three and six months ended June 30, 2024, as RYTELO was approved by the FDA in June 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250630xexx991.htm)) |
| August 6, 2025 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250630xexx991.htm)) |
| September 30, 2025 | [RYTELO (imetelstat) FDA approval](https://sec-api.dev/pdufa/imetelstat) | GERN |  | completed, approved | "The decrease in research and development expenses for the nine months ended September 30, 2025, compared to the same period in 2024, was primarily due to decreased clinical trial costs associated with a decrease of activity in our Phase 3 IMerge MDS study after FDA approval of RYTELO in 2024, as well as manufacturing and quality costs that were capitalized in the current period now that RYTELO is approved, versus being expensed in the prior period." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/886744/000088674425000071/gern-20250930.htm)) |
| November 5, 2025 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/gern-20250930xexx991.htm)) |
| February 25, 2026 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000119312526068523/d67820dex991.htm)) |
| 2H 2026 | [RYTELO (imetelstat) interim data readout](https://sec-api.dev/pdufa/imetelstat) | GERN | JAKi relapsed/refractory myelofibrosis | scheduled | "In the second half of 2026, we look forward to the IMpactMF interim analysis in relapsed/refractory myelofibrosis and the first data from real-world experience trials focused on the use of RYTELO in LR-MDS." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000119312526068523/d67820dex991.htm)) |
| August 5, 2026 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000119312526336508/d158179dex991.htm)) |
| November 4, 2026 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000119312526446203/d188608dex991.htm)) |
| Jun to Sep 2028 | [RYTELO (imetelstat) topline data readout](https://sec-api.dev/pdufa/imetelstat) | GERN | Myelofibrosis | scheduled | "NCT04576156 (A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Geron Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04576156)) |
| June 2028 | [RYTELO (imetelstat) primary completion](https://sec-api.dev/pdufa/imetelstat) | GERN | Myelofibrosis | scheduled | "NCT04576156 (A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Geron Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04576156)) |

## Drugs

- [RYTELO (imetelstat)](https://sec-api.dev/pdufa/imetelstat): jaki relapsed/refractory myelofibrosis, To treat low- to intermediate-1 risk myelodysplastic syndromes, Myelofibrosis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gern/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GERN catalysts: GERON CORP PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gern/catalysts

```bibtex
@misc{secapidev_companies_gern_catalysts_20261116,
  title        = {GERN catalysts: GERON CORP PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gern/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gern_catalysts_20261116","title":"GERN catalysts: GERON CORP PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gern/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
